Current practice and perceptions on the use of mineralocorticoid receptor antagonists in the management of heart failure: A cross-sectional study among Indian physicians

Le résumé fourni par la source

Background: Mineralocorticoid receptor antagonists (MRAs) are a key component of guideline-directed therapy for heart failure (HF). Objective: This study explored the practices and perceptions of Indian physicians regarding MRA use in HF management. Methodology: A cross-sectional digital survey was conducted among Indian physicians from November 2022 to April 2023. Results: Of 528 responses, 75% of patients had HF with reduced ejection fraction (HFrEF), while 25% had HF with preserved EF (HFpEF). Hypertension was reported in 50% of HFrEF and 75% of HFpEF patients, with diabetes being a common comorbidity in 50% overall. MRAs were preferred by 88.6% of physicians, though only 37% considered them first-line therapy. Spironolactone was favored by 54.7%, while 45.3% chose eplerenone. Most of the physicians (92%) prescribed MRAs alongside loop diuretics. Initial spironolactone dosing was 25 mg in 77.8% of cases and 50 mg in 22% of cases. Reported benefits included improved New York Heart Association class (41.1%) and reduced hospitalizations (32.6%). Hyperkalemia incidence in patients on MRA was <25%, according to 80.9% of respondents. Despite recognized benefits, 84.5% felt MRAs were underdosed, and 83.4% believed that they were underutilized. Lack of awareness was cited by 43.8% as the primary reason for not using MRAs as a first-line therapy. Conclusion: Although MRAs are widely acknowledged as effective in HF treatment, underuse and suboptimal dosing remain challenges in India, largely due to limited awareness.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.